SM
AGRX

Sabby Management’s Agile Therapeutics AGRX Stock Holding History

Sabby Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$11.3K – 134
2022
Q4 		$11.3K Hold
1,000
– – 0.01% 101
2022
Q3 		$15K Buy
+1,000
New +$24.6K 0.02% 102

Other funds holding AGRX

LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Sabby Management's AGRX Position: Q1 2023 in Review

Sabby Management sold out of Agile Therapeutics (AGRX) in Q1 2023, closing a stake of 1,000 shares — an estimated $11.3K sold.

Sabby Management first reported a position in AGRX in Q3 2022 and held it in 2 quarters. The position peaked at $15K in Q3 2022. 22 funds tracked by Wall St. Rank hold AGRX as of Q1 2023.

  • Sabby Management reported no remaining Agile Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Sabby Management sold 1,000 Agile Therapeutics shares in Q1 2023, an estimated $11.3K.
  • Sabby Management first reported a position in Agile Therapeutics in Q3 2022 and held it in 2 quarters.
  • Sabby Management's Agile Therapeutics position peaked at $15K in Q3 2022.
  • 22 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2023.

Based on Sabby Management's 13F filing for Q1 2023, filed 15 May 2023.